Journal article icon

Journal article

Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT).

Abstract:

OBJECTIVE: C-reactive protein (CRP) is closely associated with obesity and cardiovascular disease in both diabetic and nondiabetic populations. In the short term, commonly prescribed antidiabetic agents have different effects on CRP; however, the long-term effects of those agents are unknown. RESEARCH DESIGN AND METHODS: In A Diabetes Outcome Progression Trial (ADOPT), we examined the long-term effects of rosiglitazone, glyburide, and metformin on CRP and the relationship among CRP, weight, ...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.2337/dc09-1661

Authors


Journal:
Diabetes care More from this journal
Volume:
33
Issue:
1
Pages:
177-183
Publication date:
2010-01-01
DOI:
EISSN:
1935-5548
ISSN:
0149-5992
Language:
English
Keywords:
Pubs id:
pubs:46237
UUID:
uuid:1ad59f41-bbe6-43ae-bd6a-b35d6949d7b6
Local pid:
pubs:46237
Source identifiers:
46237
Deposit date:
2012-12-19

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP